Search Results
Results found for "Tao Che"
- New Tools, Smart Signals, and The Kenakin Brief
Explore Terry's Corner From Chemistry Lab to GPCR Partner – New Podcast with Celtarys Dr. Maria Majellaro of Celtarys shares how her team translates medicinal chemistry into practical GPCR assay
- How Breakthroughs Happen: Eric Trinquet on Innovation, Serendipity & GPCRs
of Discovery pHSense wasn’t built in a vacuum—it was born from decades of groundwork in rare earth chemistry It’s the product of layered collaborations—with Durham University chemist David Parker on the probe chemistry
- Understanding Enzyme Inhibition In GPCR Discovery Programs
year of expert training Unlock On-Demand Yearly Access Now — Premium Members Get Over 50% Discount at Checkout
- Enzyme Inhibition Pharmacology: The Hidden Gatekeepers of GPCR Drug Discovery
Seemed Like Magic Before modern pharmacology, enzymes were mysterious catalysts that seemed to defy chemical In this lecture, you’ll revisit the early days of discovery: when scientists thought cellular chemistry isn’t a checkbox; it’s a survival test. Yet many discovery teams still relegate them to the “ADME” checklist, rather than the strategic design
- Assay Volume Control: Your GPCR Drug Discovery Power Lever
months of expert training Unlock On-Demand Yearly Access Now — Premium Members Get Over 50% Discount at Checkout updates, priority event alerts, vetted jobs, and commentary that connects dots across pharmacology, chemistry
- The Truth About GPCR Product Launches: Years in the Making
It started not with biology—but with chemistry. Revvity and academic collaborator Prof. Mini Timeline: The Road to pHSense → Initial lanthanide probe design with Durham University (chemistry Revnity’s partnership with Durham (chemistry) and the Institute of Functional Genomics in Montpellier
- Assay Sensitivity: The Hidden Lever Driving GPCR Drug Discovery
Adjusting assay sensitivity—whether through expression systems, chemical modulation, or engineered desensitization—provides
- Orthosteric vs Allosteric Interactions— and the pHSense Shift in Internalization
GPCR members save 50%+ (check your Weekly News code). Years of chemistry, photophysics, and pharmacology condensed into one breakthrough: pHSense , a reagent Rare-earth europium complexes offered potential—but the chemistry was brutal. They translated a fundamental principle of chemistry into a usable platform for pharmacology—showing how persistence, precision, and the courage to take on “impossible” chemistry can shift the entire GPCR
- Orthosteric vs. Allosteric Interactions: The Silent Decider of Safety and Success
GPCR members save 50%+ (check your Weekly News code).
- Optimizing HTRF Assays with Fluorescent Ligands: Time-Resolved Fluorescence in GPCR Research
By combining deep expertise in GPCR biology with advanced fluorescence chemistry, Celtarys custom-developed Curr Chem Genomics. 2009 May 28;3:22-32. doi: 10.2174/1875397300903010022.
- Targeting GPCRs in the CNS: Advances in Drug Discovery Strategies
Chem Rev. 2017 Jan 11;117(1):139-155. Chem Rev. 2017 Jan 11;117(1):139-155. doi: 10.1021/acs.chemrev.6b00177 Alavi MS, Shamsizadeh A, Azhdari-Zarmehri
- How to Design GPCR Drugs That Work in Vivo: Strategy, Tools, and Insights
Unlock On-Demand Yearly Access Now — Premium Members Get Over 50% Discount at Checkout ➤ Revvity x Dr scientists actually need—and validating it where it counts. 🎧 Go behind the scenes with Revvity —from the chemistry
- GPCR Drug Discovery at Discovery on Target: Why This Track Is About More Than Receptors
Here’s who we've talked to so far: 🎥 Check out the interview with Dr. from UNC and Terry's Corner We'll continue to update this section as new videos are released — so check
- Mechanism vs. Assumption: A Model-First Path to Getting GPCR MoA Right
Unlock real SAR: Deconvolute potency into affinity vs. efficacy to make medicinal chemistry cycles more
- From Snapshots to Predictions: Why Mechanism of Action Matters
Internal checks (like requiring a Schild regression slope of unity for competitive antagonism) add further Chemists suddenly have meaningful levers to pull. The lesson: models don’t just need data. shifted curves left Sometimes it raised baseline activity Sometimes it boosted the maximum response Chemists
- How to Use Statistical Methods to Strengthen Every GPCR Drug Discovery Decision
Must-read publications: A structural modeling study revealing non-canonical mechanisms of chemokine-driven
- Applications of Fluorescent Probes in Confocal Imaging of GPCRs: From Live to Fixed Cells
Come check out our products or contact us for more information!
- GPCR Happy Hour – Boston, Sept 2025
Axxam’s capabilities span the full spectrum of GPCR families, including aminergic, peptide, lipid, and chemosensory
- Fluorescence Polarization in GPCR Research
Adapted from: Zhang Y, Tang H, Chen W, Zhang J. ACS Med Chem Lett. 2022 Jan 10;13(2):243-249. doi: 10.1021/acsmedchemlett.1c00598.
- Advantages of Fluorescent Probes in GPCR Assays
ACS Chem Biol. 2014 Sep 19;9(9):1918-28. doi: 10.1021/cb5004042.
- Differential binding of Δ9-tetrahydrocannabinol derivatives to type 1 cannabinoid receptors (CB1)
If you want to check out the Materials and Methods section as well as the application note, here is the
- A robust and Efficient FRET-Based Assay for Cannabinoid Receptor Ligands Discovery.
Chemical structure of [3H-CP-55940]. with even more diversity in chemical structures and affinities for other receptors. If you want to read the materials and methods section check out the link to the full article. Chem. Chem. 2006 , 49 (1), 70–79. https://doi.org/10.1021/jm050467q .
- Radioligands vs. Fluorescent Ligands: Binding Assays
They have several advantages, such as the minimal chemical modifications in the original ligand, high Tritium (3H) labeled ligands are usually chemically identical to the original, because tritium will usually specific activity, but a shorter half-life (60 days), which complicates storage, besides changing the chemical
- Fluorescence based HTS compatible ligand binding assays for dopamine D3 receptors in baculovirus preparations and live cells
determined to be 30.1 ± 1.7 nM corresponding to apparent Ki ± SEM = 15.7 ± 0.9 nM according to the Cheng-Prusoff Journal of Biological Chemistry 2005 , 280 (3), 2176–2185. https://doi.org/10.1074/jbc.M410385200 Chem. 2022 , 65 (6), 4832–4853. https://doi.org/10.1021/acs.jmedchem.1c02033 . (18) Dempsey, C.; Chen, K. H.; Bates, M.; Zhuang, X.
- Conjugation Strategies for Probe Development
This is Lucía from the Celtarys Research chemistry team. You can check what we do here on our website! In Comprehensive Analytical Chemistry ; Verma, S. K., Das, A. Bioconjugate Chem. 2015 , 26 (1), 145–152. https://doi.org/10.1021/bc5005262 . Chem. Rev. 2008 , 108 (8), 2952–3015. https://doi.org/10.1021/cr0783479 .
- The Imprecision Problem: Why Your GPCR Drug Discovery Program Is Off-Track Before It Even Starts
Bring in a computational chemist. Add a data scientist. Surely more hands will move the needle.
- Decoding Olfactory GPCRs: How AlphaFold and AI Are Changing the Game
That’s where computational chemistry steps in. This case study highlights why computational chemistry is no longer a side tool—it’s a driver of discovery
- GPCR Allosteric Modulation: Why Allostery is the Engine of Drug Discovery
You’ll see how this manifests in real data from muscarinic receptors, CCR5 chemokine programs, and NMDA
- Your GPCR Program Decisions Depend on Good Data Interpretation
GPCR University Learner Celtarys Research Recap: Medicinal Chemistry Highlights You May Have Missed The pace of innovation in medicinal chemistry is accelerating—and if you missed this year’s ACSMEDI-EFMC Medicinal Chemistry Frontiers 2025 , you’re already behind.
- GPCR Allostery: Unlock Hidden Mechanisms and Make Smarter Drug Decisions
. 🔍 This Week in Premium: Sneak Peek Industry insights: Strategic biotech alliances (Chemspace/Enamine






























